{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:38:37Z","timestamp":1788259117928,"version":"build-2803163510"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of hematologic malignancies, offering durable remissions for patients with otherwise refractory disease. However, access to these therapies remains limited and primarily restricted to academic medical centers, contributing to significant geographic and demographic disparities in care delivery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective review of a community practice-based outpatient CAR T-cell therapy program, independent of academic or hospital affiliation, treating patients with relapsed hematologic malignancies. The implementation process, completed over six months, followed a structured series of steps to ensure safe and effective outpatient administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between April 19, 2022, and December 18, 2024, 41 adult patients received outpatient CAR T-cell therapy. Products administered included liso-cel (n=19), ide-cel (n=12), axi-cel (n=8), and brex-cel (n=2). CRS occurred in 68% of patients, and ICANS in 22%. Hospital admission was required for 49% of patients, with 15% needing ICU care. Clinical remission rates at day 100 and 1 year were consistent with published data for each product. Patients receiving 4-1BB co-stimulatory domain CAR T-cells were observed to have numerically lower hospitalization rates (32%) compared to those receiving CD28-based products (100%). No unexpected safety concerns were observed under home-based monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This analysis demonstrates that outpatient CAR T-cell therapy can be safely delivered in a community oncology practice setting, offering a viable solution to expand access and reduce geographic barriers. Despite clinical success, payer reluctance remains a significant barrier, highlighting the urgent need for policy reform to enable community-based delivery of advanced therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1712533","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T05:18:49Z","timestamp":1771219129000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Advancing access to CAR T-cell therapy: insights and real-world experience from a community oncology practice"],"prefix":"10.3389","volume":"16","author":[{"given":"Gary L.","family":"Simmons","sequence":"first","affiliation":[{"name":"Virginia Oncology Associates","place":["Norfolk, VA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Cross","sequence":"additional","affiliation":[{"name":"Virginia Oncology Associates","place":["Norfolk, VA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias C.","family":"Pittos","sequence":"additional","affiliation":[{"name":"McKesson","place":["Irving, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S391","DOI":"10.1016\/j.jtct.2025.01.602","article-title":"Real-world treatment patterns of large B-cell lymphoma patients over time in a post-CAR T approval era","volume":"31","author":"Perales","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e20021","article-title":"ethical challenges with CAR T slot allocation with idecabtagene vicleucel manufacturing access","volume":"40","author":"Kourelis","year":"2022","journal-title":"J Clin Oncol"},{"key":"B3","unstructured":"Bringing Research to the Community to Reduce Cancer Disparities\n          \n          \n          \n          2017"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5150","DOI":"10.1182\/blood-2023-174921","article-title":"Real-world incidence, characteristics and management of cytokine release syndrome induced by chimeric antigen receptor T-cell therapy across hematologic Malignancies","volume":"142","author":"Chaudhary","year":"2023","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1182\/blood-2024-211499","article-title":"Barriers to CAR-T therapy adoption: comparing access in academic and community settings in the US","volume":"144","author":"Levent","year":"2024","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.04.017","article-title":"Chimeric antigen receptor T-cell access in patients with relapsed\/refractory large B-cell lymphoma: association of access with social determinants of health and travel time to treatment centers","volume":"30","author":"Ahmed","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0025","article-title":"Balancing value with affordability: cell immunotherapy for cancer treatment in the U.S","volume":"25","author":"Leech","year":"2020","journal-title":"Oncologist"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.11.008","article-title":"Chimeric antigen receptor T-cell therapy in the outpatient setting: an expert panel opinion from the american society for transplantation and cellular therapy","volume":"30","author":"Oluwole","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1412002","article-title":"Outpatient administration of CAR T-cell therapy: A focused review with recommendations for implementation in community based centers","volume":"15","author":"Perez","year":"2024","journal-title":"Front Immunol"},{"key":"B10","unstructured":"FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor CAR T Cell Immunotherapies\n          \n          \n          \n          2025"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2021.101277","article-title":"CAR T-cell therapy: review of the newest weapon in the battle against hematologic Malignancies","volume":"11","author":"Marjoncu","year":"2021","journal-title":"J Hematol Oncol Pharm"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e18896","article-title":"Real-world duration of hospitalization for CAR-T treatment: U.S. Patient experience in multiple hematologic Malignancies","volume":"41","author":"Kish","year":"2023","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e19501","article-title":"A national inpatient sample analysis for CAR-T cell therapy administration","volume":"40","author":"Bakalov","year":"2022","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02917-7","article-title":"Medicare utilization and cost trends for CAR T cell therapies across settings of care in the treatment of diffuse large B-cell lymphoma","volume":"41","author":"Wu","year":"2024","journal-title":"Adv Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e202072","DOI":"10.1001\/jamanetworkopen.2020.2072","article-title":"Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma","volume":"3","author":"Lyman","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-023-00232-9","article-title":"Patient perceptions of CAR-T therapy in the USA: findings from in-depth interviews","volume":"11","author":"Bixby","year":"2023","journal-title":"Oncol Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15245746","article-title":"The impact of outpatient versus inpatient administration of CAR-T therapies on clinical, economic, and humanistic outcomes in patients with hematological cancer: A systematic literature review","volume":"15","author":"Hansen","year":"2023","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1712533\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:27:23Z","timestamp":1771932443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1712533\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":17,"alternative-id":["10.3389\/fonc.2026.1712533"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1712533","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"article-number":"1712533"}}